Clinical Topics

Better Survival for NSCLC Patients Treated by Military Medicine

by U.S. Medicine

November 29, 2018

BETHESDA, MD—Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

That was the question examined in a new study published in Cancer Epidemiology, Biomarkers & Prevention. Survival of NSCLC patients treated within the MHS was compared to the U.S. general population.1

The study was led by researchers from the John P. Murtha Cancer Center, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center. MHS data for the study were from the DoD’s Automated Central Tumor Registry (ACTUR), while data for the general population came from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

The focus was on NSCLC patients diagnosed between Jan. 1, 1987, and Dec. 31, 2012, in ACTUR and a sample of SEER patients who were matched to the ACTUR patients on age group, sex, race and year of diagnosis group with a matching ratio of 1:4. Follow-up continued through Dec. 31, 2013.

Ultimately, 16,257 NSCLC patients were identified from ACTUR ,and 65,028 matched patients from SEER.

Results indicated that, Compared with SEER patients, ACTUR patients had significantly better overall survival (log-rank P < 0.001). The better overall survival among the ACTUR patients remained after adjustment for potential confounders (HR = 0.78, 95% confidence interval, 0.76-0.81).

Researchers emphasized that the survival advantage of the ACTUR patients was present regardless of cancer stage, grade, age group, sex or race.

“The MHS’s universal care and lung cancer care programs may have translated into improved survival among NSCLC patients,” study authors concluded, pointing out that their results confirms that NSCLC patients with universal care access have better outcomes.

1. Lin J, Kamamia C, Brown D, Shao S, McGlynn KA, Nations JA, Carter CA, Shriver CD, Zhu K. Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER Population. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):673-679. doi: 10.1158/1055-9965.EPI-17-0822.


Comments are closed here.


Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up